

**FACULTY AWARDS
10/1/2021 TO 09/30/2022**

DEPT	LEAD PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
UNIT: Mitchell Cancer Institute							
Mitchell Cancer Institute							
	Jones, Nathaniel	NIH	Achieving equity in endometrial cancer using DNA damage as a molecular determinant of immunotherapy response	A21-0144-002	Continuation	7/7/2022	\$166,910
	Khushman, Moh'D	NIH	Protocol N1048 (PROSPECT)	A16-0054-003	Continuation	9/30/2022	\$0
	Pierce, Jennifer	NIH	Evaluating the implementation and impact of navigator-delivered ePRO home symptom monitoring and management	A20-0227-002	Continuation	8/24/2022	\$100,000
	Pierce, Jennifer	ACS	ACS Transportation Grant	A22-0071-001	New	3/8/2022	\$10,000
	Pierce, Jennifer	ACS	ACS Patient Lodging Grant	A22-0072-001	New	3/8/2022	\$25,000
	Pierce, Jennifer	NIH	Advancing Surgical Cancer Care and Equity in the Deep South (ASCENDS)	A22-0087-001	New	4/4/2022	\$25,000
	Pierce, Jennifer	PCORI	Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer	A22-0152-001	New	9/28/2022	\$20,000
	Scalici, Jennifer	DOD	Before the chicken or the egg: Modulating ovarian hormonal and inflammatory inputs to interrupt carcinogenesis in a novel murine model of spontaneous EOC	A22-0120-001	New	6/14/2022	\$585,747
	Sobol, Robert	NSF	Greater Caribbean Center for Ciguatera Research	A18-0228-005	Continuation	7/5/2022	\$14,000
TOTAL FOR DEPARTMENT: Mitchell Cancer Institute							\$946,657

**FACULTY AWARDS
10/1/2021 TO 09/30/2022**

DEPT	LEAD PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
USA Health Clinical Trials							
	Alkharabsheh Omar	SGI	A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy	A20-0089-002	Continuation	9/30/2022	\$13,412
	Alkharabsheh Omar	ABVI	Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)	A21-0019-002	Continuation	9/28/2022	\$8,380
	Alkharabsheh Omar	LOXOI	A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	A22-0041-001	New	10/27/2021	\$46,636
	Alkharabsheh Omar	LOXOI	A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	A22-0092-001	New	10/27/2021	\$0
	Cohen, Michael	BIP	Cluster-randomized clinical trial to test the effectiveness of an innovative, clinic-level implementation strategy to improve the management of patients with T2DM and cardiovascular disease	A20-0072-003	Continuation	9/30/2022	\$5,350
	Dyess, Donna	GNTC	B59	A18-0198-005	Continuation	9/30/2022	\$25,480

**FACULTY AWARDS
10/1/2021 TO 09/30/2022**

DEPT	LEAD PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Dyess,	Donna	LUMI	MCI CT Lumicell Breast Trial	A18-0209-004	Continuation	9/30/2022	\$1,500
Dyess,	Donna	LUMI	Lumicell Pivotal Trial	A19-0230-003	Continuation	9/30/2022	\$7,829
Haynes,	Johnson	NPC	A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ? 16 years with chronic kidney disease due to sickle cell ne	A21-0088-002	Continuation	9/30/2022	\$3,100
Howard,	John	MERCK	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE	A21-0219-002	Continuation	9/30/2022	\$93,869
Jones,	Nathaniel	MERCK	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-	A21-0119-002	Continuation	9/30/2022	\$172,026
Khushman,	Moh'D	MERCK	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475)Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With MetastaticCastration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)	A20-0031-002	Continuation	9/30/2022	\$3,750
Khushman,	Moh'D	ABVI	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) inSubjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer	A20-0061-003	Continuation	9/30/2022	\$8,310

**FACULTY AWARDS
10/1/2021 TO 09/30/2022**

DEPT	LEAD PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Khushman,	Moh'D	IPSEN	An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma	A20-0125-002	Continuation	9/30/2022	\$2,600
Khushman,	Moh'D	ASTZ	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepa	A20-0202-003	Continuation	9/30/2022	\$4,080
Khushman,	Moh'D	ASTZ	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular	A20-0206-003	Continuation	9/30/2022	\$2,930
Khushman,	Moh'D	MERCK	MK7339-012 A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, L	A20-0213-003	Continuation	9/30/2022	\$6,300
Khushman,	Moh'D	NAT	BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer	A21-0065-002	Continuation	9/28/2022	\$25,250
Pai,	Sachin	CALBIO	Calithera INCB 01158-101 Solid Tumor	A18-0048-006	Continuation	9/30/2022	\$15,887
Pai,	Sachin	INC	A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors	A19-0035-004	Continuation	9/30/2022	\$6,573

**FACULTY AWARDS
10/1/2021 TO 09/30/2022**

DEPT	LEAD PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Pai,	Sachin	NIH	LUNGMAP, A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	A19-0247-003	Continuation	9/30/2022	\$0
Pai,	Sachin	NIH	SWOG 1602 BCG	A20-0027-003	Continuation	9/30/2022	\$6,714
Pai,	Sachin	MERCK	MCI Merck 5890-001 Ph 1 Solid Tumor	A20-0033-003	Continuation	9/30/2022	\$34,304
Persing,	Brian	MERCK	A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYN	A21-0089-002	Continuation	9/30/2022	\$14,368
Persing,	Brian	CALBIO	CX-839-014: A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous,	A21-0105-002	Continuation	9/30/2022	\$8,250
Persing,	Brian	NTI	A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-17 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small	A22-0139-001	New	6/1/2022	\$16,400
Pittman,	Joyce	OFL	Evaluation of Peristomal skin in ileosty participants using Ostoform moldable seal with Flowassist	A20-0065-003	Continuation	9/30/2022	\$3,660
Poosarla,	Teja	BMSI	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal	A20-0124-003	Continuation	9/30/2022	\$102,059

**FACULTY AWARDS
10/1/2021 TO 09/30/2022**

DEPT	LEAD PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Poosarla,	Teja	PFIZ	A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE AND NEGATIVE SOLID TUMORS	A21-0036-002	Continuation	9/28/2022	\$8,400
Proddaturvar,	Pranitha	SGI	SGNTUC-016 HER2+	A20-0107-003	Continuation	9/30/2022	\$66,801
Proddaturvar,	Pranitha	ASTZ	SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Hav	A21-0233-001	New	3/15/2022	\$15,701
Rocconi,	Rodney	GRDL	Gradalis 126: extension study for gradalis 119	A17-0138-005	Continuation	9/30/2022	\$19,429
Rocconi,	Rodney	CLSC	Celsion GEN 1 Ovarian	A18-0146-004	Continuation	9/30/2022	\$51,618
Rocconi,	Rodney	MERCK	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma	A20-0030-003	Continuation	9/30/2022	\$40,466
Rocconi,	Rodney	GRDL	Blood and Tissue Procurement Protocol for Product Development and Research	A21-0085-002	Continuation	9/28/2022	\$11,150
TOTAL FOR DEPARTMENT: USA Health Clinical Trials							\$852,582
TOTAL FOR UNIT: Mitchell Cancer Institute							\$1,799,239